Study of ATH-1017 for the Treatment of Alzheimer's Disease

The purpose of the study is to test if an experimental drug called ATH-1017 is safe and helpful to people with memory and thinking problems associated with Alzheimer's Disease. The study treatments, ATH-1017 or a placebo, will be assigned randomly. Nationwide, 300 participants will be recruited for this study. At Rush University Medical Center, we expect to recruit up to 15 participants.

In order to participate, you must:

• Be 55-85 years old.
• Have a diagnosis of mild to moderate Alzheimer's Disease.
• Have an individual who knows you well willing to take part in the study with you as your study partner.

You will be excluded from the study if you:

• Are unable or unwilling to complete all study activities.
• Have other medical conditions, illnesses or diseases that could interfere with study participation.

This is a partial list of inclusion and exclusion criteria.